Synergistic and tumour selective effects of chemotherapy and ultrasound treatment

Cancer Letters

Volumn 232, Issue 2, 2006, Pages 206-213

  Myhr, Gunnar ^a,b   Moan, Johan ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b CancerCure Technology Ltd   (Norway)

Author keywords

Encapsulated chemotherapeutic drugs; Enhanced response; Selectivity; Ultrasound

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; DOXORUBICIN; FLUOROURACIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON CANCER; DRUG ACTIVITY; DRUG CONCENTRATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR GROWTH; ULTRASOUND;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOXORUBICIN; FLUOROURACIL; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; ULTRASONIC THERAPY;

ANIMALIA; MUS MUSCULUS;

EID: 31644436476     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.02.020     Document Type: Article

References (17)

1. D.C. Drummond, O. Meyer, K. Hong, D.B. Kirpotin, and D. Papahadjopoulos Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol. Rev. 51 4 1999 692 737
2. G. Xu, and H.L. McLeod Strategies for enzyme/prodrug cancer therapy Clin. Cancer Res. 7 2001 3314 3324
3. L. Harris, G. Batist, and R. Belt Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Cancer 94 1 2002 25 36
4. M.E.R. O'Brien, N. Wigler, and M. Inbar Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 15 2004 440 449
5. E. Briasoulis, V. Karavasilis, and E. Tzamakou Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel Cancer Chemother. Pharmacol. 53 5 2004 452 457
6. A. Vorobiof, B.L. Rapoport, and M.R. Chasen First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study Breast 13 3 2004 219 226
7. R.J. Francis, S.K. Sharma, and C. Springer Phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours Br. J. Cancer 87 6 2002 600 6007
8. A. Mayer, S.K. Sharma, and B. Tolner Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antiboby-directed enzyme prodrug therapy (ADEPT) Br. J. Cancer 9 12 2004 2402 2410
9. N. Rapoport, W.G. Pitt, H. Sun, and J.L. Nelson Drug delivery in polymeric micelles: from in vitro to in vivo J. Control Release 91 1-2 2003 85 95
10. J.L. Nelson, B.L. Roeder, J.C. Carmen, F. Roloff, and W.G. Pitt Ultrasonically activated chemotherapeutic drug delivery in a rat model Cancer Res. 62 24 2002 7280 7283
11. L.E. Kinsler, R.F. Austin, A.B. Coppens, and J.V. Sanders Fundamentals of Acoustics 1982 Wiley New York
12. T.G. Leighton, A.J. Walton, and M.J. Pickworth Primary Bjerknes forces Eur. J. Phys. 11 1990 47 50
13. C.W. Brennen Cavity and Bubble Dynamics 1995 Oxford University Press New York
14. P. Ragnhammar, L. Hafstrom, P. Nygren, and B.A. Glimelius Systematic overview of chemotherapy effects in colorectal cancer Acta Oncol. 40 2-3 2001 281 308
15. M.G. Rose, M.P. Farrell, and J.C. Schmitz Thymidylate synthase: a critical target for cancer chemotherapy Clin. Colorectal Cancer 1 4 2002 220 229
16. G. Myhr, Apparatus for selective cell and virus destruction within a living organism, PCT/NO 01/00349 (WO 02 15976), 2002.
17. G. Myhr, Therapeutic probe, method and system. US Patent Application No. 10/610531, PCT/NO04/00206, 2003/04.